Imbruvica and The flu - a phase IV clinical study of FDA data

Summary:

The flu is reported as a side effect among people who take Imbruvica (ibrutinib), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Amlodipine, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have The flu when taking Imbruvica. It is created by eHealthMe based on reports of 69,938 people who have side effects when taking Imbruvica from the FDA, and is updated regularly.

What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 70,020 Imbruvica users. Check the latest studies of Imbruvica.

What is The flu?

The flu (the flu is caused by an influenza virus) is found to be associated with 2,196 drugs and 2,707 conditions by eHealthMe. Check the latest studies of The flu.

On Mar, 08, 2026

69,938 people reported to have side effects when taking Imbruvica.
Among them, 547 people (0.78%) have The flu.

Among these 547 people:

* Approximation only. Some reports may have incomplete information.

Do you take Imbruvica and have The flu?

- Check whether The flu is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Imbruvica:

Imbruvica (70,020 reports)

The flu treatments and more:

The flu (145,738 reports)

How severe was The flu and when was it recovered:

The flu in Imbruvica

Expand to all the drugs that have ingredients of ibrutinib:

The flu and drugs with ingredients of ibrutinib (611 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Imbruvica:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with The flu:

The flu (2,196 drugs)

Browse all the conditions that are associated with The flu:

The flu (2,707 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Imbruvica) and Imbruvica (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.